Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Montana Wildhack who wrote (8875)	2/22/2002 3:09:29 PM
From: Montana Wildhack	Read Replies (1) \| Respond to of 14101

Dimethaid responds to Health Canada TORONTO, Feb. 22 /CNW/ - Dimethaid Research Inc. (TSE: DMX) announced today that it has filed its response to the issues raised by the Therapeutic Products Directorate after its review of the Company's New Drug Submission for PENNSAID Topical Solution. Health Canada will now have 45 days to screen the Company's response for completeness and a further 150 days for review. "Because PENNSAID(R) is a product, invented, developed and manufactured in Canada, we had anticipated that Canadian marketing authorization would be granted ahead of the other jurisdictions where applications for approval were subsequently submitted," said Rebecca Keeler, President and CEO. "While we await the timely review of the responses filed today, we will be expanding the commercialization of PENNSAID(R) from the United Kingdom to other European Union member states and look forward to the day when we can also offer North American osteoarthritis patients the option of a safe and effective topical treatment for their symptoms."